Business ❯Finance ❯Corporate Earnings

Pharmaceuticals

Eli Lilly Bristol Myers Squibb Novo Nordisk Pfizer Merck

Eli Lilly Reports Mixed Q4 Results as Key Drug Sales Fall Short of Expectations

Bristol Myers Squibb Predicts 2025 Revenue Decline, Expands Cost-Cutting Measures

Pfizer Reports Strong Q4 Earnings But Faces Uncertain Market Sentiment

Merck Cuts 2025 Revenue Forecast After Halting Gardasil Shipments to China

Bristol Myers Squibb Surpasses Q3 Expectations, Raises 2024 Outlook